Cannabinoids in Medicine: A Multifaceted Exploration of Types, Therapeutic Applications, and Emerging Opportunities in Neurodegenerative Diseases and Cancer Therapy

Cannabinoids are a diverse group of compounds that interact with the body's endocannabinoid system (ECS), a complex neuromodulatory network involved in synaptic plasticity and homeostasis. These compounds are categorized into three types: phytocannabinoids (plant-derived, such as THC and CBD), endocannabinoids (naturally occurring, such as anandamide and 2-AG), and synthetic cannabinoids. Research into these compounds has expanded significantly, moving beyond their well-known psychoactive properties to explore their potential in treating chronic conditions, including neurodegenerative disorders and various cancers.

Neurodegenerative diseases, such as Alzheimer’s, Parkinson’s, and Huntington’s, are characterized by progressive neuronal loss and neuroinflammation. Cannabinoids have shown promise in these areas by acting on CB1 and CB2 receptors to mitigate excitotoxicity, oxidative stress, and glial activation. For instance, CBD has demonstrated neuroprotective properties in animal models of Alzheimer’s disease by reducing beta-amyloid-induced toxicity. Similarly, cannabinoids are being investigated for their ability to alleviate motor symptoms in Parkinson’s and Huntington’s diseases, though clinical evidence remains sparse and inconsistent compared to the robust preclinical findings.

In oncology, cannabinoids are being studied not only for palliative care—such as managing chemotherapy-induced nausea and pain—but also for their potential antineoplastic effects. Preclinical studies indicate that cannabinoids can induce apoptosis, inhibit cell proliferation, and suppress angiogenesis in various cancer cell lines, including glioma and breast cancer. The mechanism often involves the modulation of mitochondrial function and the induction of oxidative stress within cancer cells. Despite these promising results, the transition to human clinical practice is hindered by the lack of large-scale, well-designed trials and the need to distinguish between the therapeutic benefits of non-psychoactive compounds like CBD and the psychotropic effects of THC.